Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Moved with Pharmaceuticals peers: RYTM +21.67% · VRDN +15.49% · XNCR +14.26%
From market data · Not investment advice
Moved with Pharmaceuticals peers: RYTM +21.67% · VRDN +15.49% · XNCR +14.26%
From market data: the larger companies in its group moved the same way. No report names a cause yet.
Last check 7:30 PM ET
From market data · Not investment adviceSign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about CYTK?
Zacks Investment Research
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Cytokinetics is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +0.44% and Zacks Rank #3 (Hold). The company is projected to report a quarterly loss of $1.50 per share with revenues of $42.01 million, up 2065.5% year-over-year. The stock has beaten consensus EPS estimates in 2 of the last 4 quarters.
GlobeNewswire Inc.
Cytokinetics to Announce Third Quarter Results on November 4, 2026Cytokinetics announced it will report third quarter 2026 results on November 4, 2026, followed by a conference call. The company highlighted positive progress with MYQORZO® (aficamten) approved across multiple regions for obstructive hypertrophic cardiomyopathy, and plans to submit a Supplemental New Drug Application in Q4 2026 following positive Phase 3 results for non-obstructive HCM treatment.
Headlines open the publisher's site.
$CYTK filed an 8-K with results (Item 2.02) at 4:05 PM ET on Wed, Nov 4.
Community opinions, not advice. Posts with a target get a receipt. How receipts work ›
